Preliminary studies on exo-PD-L1 in ovarian cancer suggest that low levels of exo-PD-L1 may contribute to this poor response, but further research is needed to better understand its potential as a biomarker in this setting. This evidence concerns the gene CD274 and ovarian carcinoma.